Weight-dependent and weight-independent effects of dulaglutide on blood pressure in patients with type 2 diabetes.

Ferdinand, Keith C; Dunn, Julia; Nicolay, Claudia; Sam, Flora; Blue, Emily K; Wang, Hui

Ferdinand, Keith C; Dunn, Julia; Nicolay, Claudia; Sam, Flora; Blue, Emily K; Wang, Hui.

Affiliation

Ferdinand KC; Tulane University School of Medicine, New Orleans, LA, USA. kferdina@tulane.edu.
Dunn J; Eli Lilly and Company, Indianapolis, IN, USA.
Nicolay C; Eli Lilly and Company, Indianapolis, IN, USA.
Sam F; Eli Lilly and Company, Indianapolis, IN, USA.
Blue EK; Eli Lilly and Company, Indianapolis, IN, USA.
Wang H; TechData Service Company, King of Prussia, PA, USA.

Cardiovasc Diabetol ; 22(1): 49, 2023 03 09.

Article in En | MEDLINE | ID: mdl-36894938

Subject(s)

Diabetes Mellitus, Type 2; Humans; Diabetes Mellitus, Type 2/diagnosis; Diabetes Mellitus, Type 2/drug therapy; Blood Pressure; Hypoglycemic Agents/adverse effects; Glucagon-Like Peptides/adverse effects; Immunoglobulin Fc Fragments/adverse effects; Recombinant Fusion Proteins/adverse effects; Glucagon-Like Peptide 1/therapeutic use

Key words

Blood pressure; Diabetes; Dulaglutide; Glucagon-like peptide-1; Hypertension; Weight

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Diabetes Mellitus, Type 2 Type of study: Clinical_trials / Diagnostic_studies / Systematic_reviews Limits: Humans Language: En Journal: Cardiovasc Diabetol Journal subject: ANGIOLOGIA / CARDIOLOGIA / ENDOCRINOLOGIA Year: 2023 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google